



Advanced Research on Nanomaterials for Regenerative Medicine

Guest Editor:

Dr. Eleni Papachristou

Laboratory of Biochemistry,
School of Chemistry, Faculty of
Sciences, Aristotle University of
Thessaloniki, University Campus,
54124 Thessaloniki, Greece

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Dear Colleagues,

Nowadays, the development of biomaterials has entered the “nanotechnology era”. Within this Special Issue, we will discuss current advances in nano/biomaterials research, tissue engineering applications, drug delivery systems, nanotechnology-based disease detection systems, and development of therapeutic approaches using “intelligent nano or biomaterials”.

This Special Issue is open for the submission of basic and clinical research, also cover original articles and reviews on the following topics:

- Novel therapeutic approaches including biomaterials.
- Drug delivery systems.
- Nanotechnology-based mesenchymal stem cell therapy.
- Bioactive signals delivery for mesenchymal stem cell differentiation.
- Application of nano materials in osteogenesis, chondrogenesis, angiogenesis, neurogenesis, etc.
- Clinical trials/research on nanobiomaterials.
- Tissue engineering.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)